105 related articles for article (PubMed ID: 15222026)
1. Primary targeting of recombinant Fv-immunotoxin hscFv(25)-mTNFalpha against hepatocellular carcinoma.
Zhang J; Liu YF; Yang SJ; Qiao Q; Cheng H; Zhang CS; Ma FC; Guo HZ
World J Gastroenterol; 2004 Jul; 10(13):1872-5. PubMed ID: 15222026
[TBL] [Abstract][Full Text] [Related]
2. [Construction, expression and targeting therapeutic of single-chain immunotoxin against hepatocellular carcinoma].
Zhang J; Liu YF; Yang SJ; Qiao Q; Cheng H; Ma FC; Chen WL
Zhonghua Gan Zang Bing Za Zhi; 2004 Mar; 12(3):148-50. PubMed ID: 15059298
[TBL] [Abstract][Full Text] [Related]
3. [Targeting studies of humanized scFv25 fusing to TNFalpha against hepatocellular carcinoma].
Sun Z; Liu Y; Yuan Q; Yu W; Huang C; Ma L; Yu J
Zhonghua Gan Zang Bing Za Zhi; 2000 Dec; 8(6):352-4. PubMed ID: 11135695
[TBL] [Abstract][Full Text] [Related]
4. Anti-hepatoma human single-chain Fv antibody and adriamycin conjugates with potent antitumor activity.
Chen L; Liu YH; Li YH; Jiang Y; Xie PL; Zhou GH; Li GC
Int Immunopharmacol; 2014 Jan; 18(1):20-6. PubMed ID: 24239629
[TBL] [Abstract][Full Text] [Related]
5. A new recombinant immunotoxin hscFv-ETA' demonstrates specific cytotoxicity against chronic myeloid leukemia cells in vitro.
Zhu X; Tao K; Li Y; Li S; Zhang L; Wang D; Zhong L; Feng W
Immunol Lett; 2013; 154(1-2):18-24. PubMed ID: 23954809
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
[TBL] [Abstract][Full Text] [Related]
7. Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin.
Shinohara H; Fan D; Ozawa S; Yano S; Van Arsdell M; Viner JL; Beers R; Pastan I; Fidler IJ
Int J Oncol; 2000 Oct; 17(4):643-51. PubMed ID: 10995873
[TBL] [Abstract][Full Text] [Related]
8. [Cloning and expression of single chain Fv gene against human colorectal carcinoma].
Fang J; Song JD
Ai Zheng; 2002 Jul; 21(7):740-4. PubMed ID: 12479098
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
10. In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein.
Cooke SP; Pedley RB; Boden R; Begent RH; Chester KA
Bioconjug Chem; 2002; 13(1):7-15. PubMed ID: 11792173
[TBL] [Abstract][Full Text] [Related]
11. Targeted Cancer Therapy Using Fusion Protein of TNFα and Tumor-Associated Fibronectin-Specific Aptide.
Jeon H; Kim D; Choi M; Kang S; Kim JY; Kim S; Jon S
Mol Pharm; 2017 Nov; 14(11):3772-3779. PubMed ID: 28969419
[TBL] [Abstract][Full Text] [Related]
12. A genetically engineered single-chain FV/TNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor.
Yang J; Moyana T; Xiang J
Mol Immunol; 1995 Aug; 32(12):873-81. PubMed ID: 7565814
[TBL] [Abstract][Full Text] [Related]
13. Survivin knockdown by short hairpin RNA abrogates the growth of human hepatocellular carcinoma xenografts in nude mice.
Zhang R; Ma L; Zheng M; Ren J; Wang T; Meng Y; Zhao J; Jia L; Yao L; Han H; Li K; Yang A
Cancer Gene Ther; 2010 Apr; 17(4):275-88. PubMed ID: 19876077
[TBL] [Abstract][Full Text] [Related]
14. [Construction and expression of a hepatocellular carcinoma specific rodent and its humanized single-chain Fv fragments in Escherichia coli].
Yuan QA; Yu WY; Huang CF
Sheng Wu Gong Cheng Xue Bao; 2000 Jan; 16(1):86-90. PubMed ID: 10883284
[TBL] [Abstract][Full Text] [Related]
15. Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery.
Li L; Huang JL; Liu QC; Wu PH; Liu RY; Zeng YX; Huang WL
World J Gastroenterol; 2004 Jul; 10(13):1867-71. PubMed ID: 15222025
[TBL] [Abstract][Full Text] [Related]
16. Ad-KDRscFv:sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues.
Yang L; Guo J; Wang J; Wan S; Yang S; Wang R; Chen W; Peng G; Fang D
Int Immunopharmacol; 2012 May; 13(1):37-45. PubMed ID: 22406047
[TBL] [Abstract][Full Text] [Related]
17. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.
Reiter Y; Pastan I
Clin Cancer Res; 1996 Feb; 2(2):245-52. PubMed ID: 9816166
[TBL] [Abstract][Full Text] [Related]
18. Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice.
Gao Y; Yao A; Zhang W; Lu S; Yu Y; Deng L; Yin A; Xia Y; Sun B; Wang X
Oncogene; 2010 May; 29(19):2784-94. PubMed ID: 20190814
[TBL] [Abstract][Full Text] [Related]
19. Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor.
Liu Y; Cheung LH; Marks JW; Rosenblum MG
Int J Cancer; 2004 Feb; 108(4):549-57. PubMed ID: 14696119
[TBL] [Abstract][Full Text] [Related]
20. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X
Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
